Viridian Therapeutics, Inc. (VRDN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Viridian Therapeutics, Inc. (VRDN)
Company Performance

Current Price

as of Oct 16, 2024

$23.79

P/E Ratio

N/A

Market Cap

$1.82B

Description

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Metrics

Overview

  • HQWaltham, MA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerVRDN
  • Price$23.79-1.04%

Trading Information

  • Market Cap$1.82B
  • Float89.05%
  • Average Daily Volume (1m)1,123,183
  • Average Daily Volume (3m)1,452,294
  • EPS-$4.25

Company

  • Revenue$0.29M
  • Rev Growth (1yr)N/A
  • Net Income-$64.99M
  • Gross Margin-652.78%
  • EBITDA Margin-99,506.94%
  • EBITDA-$71.65M
  • EV$481.65M
  • EV/Revenue1,672.39
  • P/EN/A
  • P/S5,274.65
  • P/B4.61
Documents
SEC Filings
8-K (2024-09-12)
8-K (2024-09-10)
8-K (2024-08-08)
8-K (2024-07-15)
8-K (2024-06-20)
8-K (2024-05-08)
8-K (2024-04-16)
8-K (2024-02-27)
8-K (2024-01-19)
8-K (2024-01-08)
8-K (2023-12-18)
8-K (2023-11-13)
8-K (2023-11-02)
8-K (2023-10-30)
8-K (2023-09-25)
8-K (2023-09-12)
8-K (2023-07-17)
8-K (2023-07-10)
8-K (2023-06-16)
8-K (2023-05-09)
8-K (2023-04-12)
8-K (2023-03-10)
8-K (2023-03-08)
8-K (2023-02-06)
8-K (2023-01-09)
10-Q (2024-08-08)
10-Q (2024-05-08)
10-Q (2023-11-13)
10-Q (2023-08-08)
10-Q (2023-05-10)
10-K (2024-02-27)
10-K (2023-03-09)
Earnings Calls
Earnings Report 2024Q1
Earnings Report (2023-05-13)
Factset Street Account
Viridian Therapeutics reports Q3 EPS ($1.09) vs FactSet ($1.25) [14 est, ($1.44)-(0.98)] ($13.98, 0.00) (2023-11-13T21:03:19Z)
Viridian Therapeutics announces departure of President/CEO Scott Myers, a preclinical portfolio of FcRn inhibitors, and $185M private placement ($12.38, 0.00) (2023-10-30T12:38:47Z)
Viridian Therapeutics and Ypsomed AG sign supply agreement ($11.67, 0.00) (2023-10-26T12:08:02Z)
Viridian announces clinical data in healthy volunteer study and selects VRDN-003 as potential best-in-class subcutaneous anti-IGF-1R program with extended half-life for pivotal development in thyroid eye disease ($19.22, 0.00) (2023-12-18T12:04:06Z)
Follow-up: Viridian announces clinical data in healthy volunteer study and selects VRDN-003 as potential best-in-class subcutaneous anti-IGF-1R program with extended half-life for pivotal development in thyroid eye disease ($19.22, 0.00) (2023-12-18T12:06:13Z)